NFKB1 and inflammatory bowel disease: Indeed inflammatory bowel disease and experimental intestinal inflammation are characterized by NF-κB activation and increased expression of pro-inflammatory NF-κB target genes; accordingly, NF-κB inhibition protects against chronic intestinal inflammation and necrotizing enterocolitis in animal models [30].